Ovid Therapeutics Inc.

NasdaqGS:OVID 주식 보고서

시가총액: US$83.7m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Ovid Therapeutics 관리

관리 기준 확인 3/4

Ovid Therapeutics' CEO는 Jeremy Levin, Mar2015 에 임명되었습니다 의 임기는 9.42 년입니다. 총 연간 보상은 $ 2.14M, 29.3% 로 구성됩니다. 29.3% 급여 및 70.7% 보너스(회사 주식 및 옵션 포함). 는 $ 4.13M 가치에 해당하는 회사 주식의 5.15% 직접 소유합니다. 4.13M. 경영진과 이사회의 평균 재임 기간은 각각 3.1 년과 3.2 년입니다.

주요 정보

Jeremy Levin

최고 경영자

US$2.1m

총 보상

CEO 급여 비율29.3%
CEO 임기9.6yrs
CEO 소유권5.1%
경영진 평균 재임 기간3.3yrs
이사회 평균 재임 기간3.4yrs

최근 관리 업데이트

Recent updates

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 09

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Nov 10
We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Jun 27
Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Mar 13
Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Sep 09
Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04

Aug 09

We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Jun 09
We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Ovid Therapeutics: Good Entry Point For Investors

Jun 18

Ovid Therapeutics appoints Jeff Rona as CFO

Jun 04

Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Apr 16
Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Mar 20
Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Mar 18
Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Mar 01
We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Jan 25
Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Revisiting Ovid Therapeutics

Jan 14

Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Dec 21
Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Ovid Therapeutics misses goal in Angelman syndrome treatment

Dec 01

CEO 보상 분석

Jeremy Levin 의 보수는 Ovid Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$30m

Mar 31 2024n/an/a

-US$51m

Dec 31 2023US$2mUS$625k

-US$52m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$51m

Dec 31 2022US$3mUS$607k

-US$54m

Sep 30 2022n/an/a

-US$68m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$847kUS$584k

US$120m

Sep 30 2021n/an/a

US$123m

Jun 30 2021n/an/a

US$117m

Mar 31 2021n/an/a

US$110m

Dec 31 2020US$2mUS$560k

-US$81m

Sep 30 2020n/an/a

-US$76m

Jun 30 2020n/an/a

-US$76m

Mar 31 2020n/an/a

-US$67m

Dec 31 2019US$3mUS$530k

-US$60m

Sep 30 2019n/an/a

-US$56m

Jun 30 2019n/an/a

-US$53m

Mar 31 2019n/an/a

-US$53m

Dec 31 2018US$3mUS$530k

-US$52m

Sep 30 2018n/an/a

-US$50m

Jun 30 2018n/an/a

-US$46m

Mar 31 2018n/an/a

-US$44m

Dec 31 2017US$2mUS$515k

-US$65m

보상 대 시장: Jeremy 의 총 보상 ($USD 2.14M )은 US 시장( $USD 680.04K ).

보상과 수익: Jeremy 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jeremy Levin (71 yo)

9.6yrs

테뉴어

US$2,136,546

보상

Dr. Jeremy Max Levin, M.D., Ph D., BA Zoology, DPhil, MB BChir, serves as Director of Graviton BioScience Corporation from May 2023. He is Member of Advisory Board at New Rhein Healthcare Investors LLC.He...

리더십 팀

이름위치테뉴어보상소유권
Jeremy Levin
President9.6yrsUS$2.14m5.15%
$ 4.3m
Jeffrey Rona
Chief Business and Financial Officer3.3yrsUS$1.08m0.019%
$ 16.2k
Dirk Haasner
Senior Vice President of Global Manufacturing & CMC QA8.6yrsUS$1.18m데이터 없음
Julia Tsai
Senior Vice President of Clinical Development3.3yrs데이터 없음데이터 없음
Meg Alexander
Chief Strategy Officer2.2yrs데이터 없음데이터 없음
Toshiya Nishi
Head of Epilepsy Research1.7yrs데이터 없음데이터 없음
Zhong Zhong
Chief Scientific Officer1.3yrs데이터 없음데이터 없음
Tom Parry
Vice President of Research and Early Developmentno data데이터 없음데이터 없음

3.3yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 관리: OVID 의 관리팀은 경험 ( 2.9 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Jeremy Levin
President10.5yrsUS$2.14m5.15%
$ 4.3m
Robert Langer
Chairman of the Scientific & Clinical Advisory Board3.5yrs데이터 없음데이터 없음
Barbara Duncan
Independent Director7.3yrsUS$86.66k0%
$ 0
Bart Friedman
Lead Independent Director8.9yrsUS$104.16k0%
$ 0
Robert Poole
Independent Director3.3yrsUS$79.16k0%
$ 0
Jacqueline A. French
Member of Scientific & Clinical Advisory Board7.8yrs데이터 없음데이터 없음
Karen Bernstein
Independent Director9.1yrsUS$91.66k0.028%
$ 23.6k
Raman Sankar
Member of Scientific Advisory Boardless than a year데이터 없음데이터 없음
Kevin Fitzgerald
Independent Director3yrsUS$71.66k0%
$ 0
Jeffrey Noebels
Member of Scientific Advisory Boardless than a year데이터 없음데이터 없음
Imad Najm
Member of Scientific Advisory Boardless than a year데이터 없음데이터 없음
Jamie Maguire
Member of Scientific Advisory Boardless than a year데이터 없음데이터 없음

3.4yrs

평균 재임 기간

71yo

평균 연령

경험이 풍부한 이사회: OVID 의 이사회는 경험(평균 재직 기간 4.3 년)으로 간주됩니다.